MEDIHONEY® Gel Versus Collagenase for Wound Debridement

NCT ID: NCT02482948

Last Updated: 2017-12-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2017-03-31

Brief Summary

The purpose of this study is to compare how well two products, Active Leptospermum Honey (ALH) (MEDIHONEY® Gel) and Collagenase (Santyl®), in removing the nonviable (non living) tissue.

Detailed Description

BACKGROUND

An important aspect of wound bed preparation for healing or grafting is the recognition that wounds often have underlying pathogenic abnormalities that cause necrotic tissue to accumulate. Therefore, in order to facilitate wound progression, repeated removal of necrotic tissue may be necessary as long as the wound is chronic. Debridement is defined as the removal of nonviable material, foreign bodies, and poorly healing tissue from a wound. Although surgeons recognize the importance of debridement, few data have been generated in randomized trials to support its use. Traditionally, debridement has been undertaken as a single therapeutic step within defined time frames. The most direct form of debridement is surgical excision. Although this may be applicable for acute wounds, it is unlikely to remove the necrotic burden that may continually accumulate in a chronic wound. Although there are other forms of debridement including enzymatic and biologic; in the case of non-healing wounds, the form of debridement with the most compelling evidence of healing efficacy is autolytic debridement , Therefore, for patients who are poor candidates for surgical debridement or have limited access to a surgeon, autolytic debridement may be considered an effective form of continuous debridement.

2.1 Primary Objective

The primary objective of this study is to evaluate the non-inferiority of MEDIHONEY® Gel (Active Leptospermum Honey-ALH Gel) compared to (Santyl) Collagenase, two FDA cleared/approved treatments, with respect to the percent reduction of necrotic (including slough and eschar) tissue in the wound at the end of 14 days +/- 2 days.

2.2 Secondary Objective

The secondary objective of this study is to compare the two treatment groups with respect to the percent reduction from randomization for necrotic tissue (including slough and eschar) at weeks 1, 3 and 4 +/- 2 days.

Conditions

Ulcer; Wounds

Keywords

Debridement; collagenase; leptospermum honey

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Collagenase

This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily

Group Type: ACTIVE_COMPARATOR

Collagenase

Intervention Type: DRUG

Study agent to be applied daily to the wound.

Active leptospermum honey

This is an active medicinal grade honey used to promote autolytic debridement and applied daily

Group Type: ACTIVE_COMPARATOR

Active Leptospermum Honey (Medihoney)

Intervention Type: DEVICE

STudy agent to be applied to the wound daily.

Interventions

Active Leptospermum Honey (Medihoney)

STudy agent to be applied to the wound daily.

Intervention Type: DEVICE

Collagenase

Study agent to be applied daily to the wound.

Intervention Type: DRUG

Other Intervention Names

Medihoney; Santyl

Eligibility Criteria

Inclusion Criteria

• A signed and dated informed consent has been obtained from the subject.
• Subject is able and willing to comply with study procedures.
• Subject is able to comply with weekly visits.
• Subject is 18 years of age or older.
• There is presence of at least 50% or greater necrotic tissue (including slough and eschar) in the wound bed and a total wound surface area of > 1cm2 to < 64cm2.
• Subject will not have currently used parenteral or oral antibiotics except for UTI.
• Diabetic subjects: HbA1c < 12.0 % within 90 days preceding enrollment.
• Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment.
• Subject with a pressure ulcer must be currently receiving adequate pressure redistribution to the affected area via group 2 or 3 specialty bed, a static wheel chair cushion while patient is out of bed.
• Subject with diabetic plantar surface ulcer will use an offloading boot if ambulatory.
• Subject with a venous ulcer must be currently receiving and using compression therapy that can be managed daily.
• Subject and caregiver are trainable and able to perform dressing changes.
• Subject has no allergies to collagenase or honey.
• Subject has no allergies to semi-occlusive or absorptive secondary dressing.

Exclusion Criteria

• Steroid use >5mg daily.
• Subject is unable to cooperate with offloading and/or compression recommendations.
• ABI = or >0.8 if the wound is located on a lower extremity.
• Wound has the presence of callus requiring sharp or surgical debridement within 3 days prior to randomization and/or needs debridement using any method other than the study agent throughout study treatment.
• Subject has medical instability as deemed by the investigator.
• Subject is pregnant.
• Subject has participated in another clinical trial or wound dressing evaluation in the 30 days prior to enrollment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Integra LifeSciences Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ravi Patel, MD

Role: PRINCIPAL_INVESTIGATOR

Innovative Healing Systems

Locations

Innovative Healing Systems

Tampa, Florida, United States

Countries

United States

Other Identifiers

Derma-MH001

Identifier Type: -

Identifier Source: org_study_id